Prostate Cancer - Results from #160

Partial prostatectomy for localized prostate cancer. October 1, 2024

Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study. October 1, 2024

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). October 1, 2024

The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer. October 1, 2024

Adverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway. October 1, 2024

Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics September 30, 2024

Teleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting September 30, 2024

Identification of blood lipid markers of docetaxel treatment in prostate cancer patients. September 30, 2024

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance. September 30, 2024

Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. September 30, 2024

Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer. September 30, 2024

Preclinical and clinical evidence for using perinatal tissue allografts in nerve sparing robot assisted radical prostatectomy to hasten recovery of functional outcomes: a literature review. September 30, 2024

Results after Four Years of Screening for Prostate Cancer with PSA and MRI. September 29, 2024

Sociodemographic disparities in prostate cancer imaging. September 27, 2024

Body composition in recurrent prostate cancer and the role of steroidogenic genotype. September 27, 2024

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer. September 27, 2024

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection. September 27, 2024

DNA Methylation-Derived Immune Cell Proportions and Cancer Risk in Black Participants. September 27, 2024

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer September 26, 2024

Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. September 26, 2024

Page 9 of 1435